Eli Lilly and Company (LLY) Balance Sheet

The balance sheet is expanding rapidly, with total assets growing from $63.9B to $142.3B over ten quarters, a 122% increase. This growth is fueled by a doubling of total debt to $54.9B and a significant rise in PPE, reflecting heavy capital expenditure on manufacturing capacity. The equity base also expanded from $12.8B to $33.9B, driven by retained earnings, but the pace of asset growth outpaces equity, indicating increasing leverage. This trajectory suggests a deliberate strategy to scale production for the GLP-1 franchise, but it also raises the stakes on the success of these investments.

Total debt has more than doubled from $26.2B to $54.9B over the period, while equity grew from $12.8B to $33.9B, causing D/E to fluctuate but remain elevated. The D/E ratio peaked at 2.43 in 2025Q1 and has since declined to 1.62, suggesting a slight deleveraging as earnings accumulate. However, the absolute debt level is substantial, and the company's reliance on debt to fund expansion suggests a strategic bet on future cash flows from the metabolic portfolio. Investors should monitor the cost of this debt and the company's ability to service it if growth slows.

The asset base is increasingly dominated by property, plant, and equipment, which now represents over 20% of total assets, up from 21% in 2024Q1. This reflects massive investment in sterile fill-finish and manufacturing capacity for GLP-1 drugs, a strategic move to secure supply and reduce reliance on third-party manufacturers. Goodwill also increased from $4.9B to $8.8B, partly due to acquisitions, which introduces potential impairment risk if the acquired assets underperform. The shift toward tangible assets suggests a more asset-heavy model, which could impact returns on assets if demand does not meet expectations.

Equity has grown from $12.8B to $33.9B, primarily driven by retained earnings, which more than doubled to $31.9B. This indicates that the company is reinvesting a significant portion of its profits back into the business, supporting its growth strategy. The ROE of 101.2% is exceptionally high, reflecting both strong earnings and a relatively small equity base due to leverage. However, the company has also engaged in share repurchases, spending $1.6B in 2026Q2, which may signal confidence in the stock but also reduces the equity cushion. The quality of equity is high, but the concentration of earnings in the GLP-1 franchise poses a risk if that segment faces headwinds.

The current ratio has remained relatively stable around 1.3-1.5, indicating adequate short-term liquidity. Cash and cash equivalents increased from $2.5B to $8.9B, a significant improvement, which provides a buffer for operational needs and potential shocks. However, the current ratio is not particularly high, and the company's heavy capital expenditure and debt service requirements may strain liquidity if cash flows falter. The cash position is still modest relative to total debt, suggesting that the company relies on ongoing cash generation to meet obligations.